AORT - Artivion, Inc. Stock Price, Fair Value and News

20.75USD+0.43 (+2.12%)Market Closed

Market Summary

USD20.75+0.43

Market Closed

2.12%

AORT Stock Price

View Fullscreen

AORT RSI Chart

AORT Valuation

Market Cap

837.7M

Price/Earnings (Trailing)

-27.3

Price/Sales (Trailing)

2.37

EV/EBITDA

40.48

Price/Free Cashflow

73.51

AORT Price/Sales (Trailing)

AORT Profitability

EBT Margin

-6.10%

Return on Equity

-10.89%

Return on Assets

-3.87%

Free Cashflow Yield

1.36%

AORT Fundamentals

AORT Revenue

Revenue (TTM)

354.0M

Rev. Growth (Yr)

17.98%

Rev. Growth (Qtr)

6.62%

AORT Earnings

Earnings (TTM)

-30.7M

Earnings Growth (Yr)

-283.26%

Earnings Growth (Qtr)

59.44%

Breaking Down AORT Revenue

52 Week Range

13.0420.85

(Low)(High)

Last 7 days

-0.1%

Last 30 days

-0.6%

Last 90 days

15.5%

Trailing 12 Months

40.2%

How does AORT drawdown profile look like?

AORT Financial Health

Current Ratio

4.85

Debt/Equity

1.08

Debt/Cashflow

0.06

AORT Investor Care

Shares Dilution (1Y)

1.65%

Diluted EPS (TTM)

-0.75

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	319.8M	328.7M	339.7M	354.0M
2022	305.0M	309.2M	313.8M	313.8M
2021	257.9M	280.3M	287.3M	298.8M
2020	275.1M	257.8M	255.0M	253.2M
2019	268.4M	271.0M	274.3M	276.2M
2018	206.6M	227.3M	247.9M	262.8M
2017	182.4M	183.2M	181.9M	189.7M
2016	155.1M	166.6M	175.2M	180.4M
2015	142.7M	143.6M	143.2M	145.9M
2014	141.0M	142.1M	142.9M	144.6M
2013	135.0M	135.3M	138.1M	140.8M
2012	121.7M	125.5M	129.3M	131.7M
2011	117.1M	117.2M	118.5M	119.6M
2010	0	113.3M	115.0M	116.6M
2009	0	0	0	111.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Artivion, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 20, 2024	stanton marshall s.	sold	-44,511	20.39	-2,183	svp, clinical & md affair
Mar 15, 2024	green andrew m	sold	-29,240	20.00	-1,462	vp regulatory
Mar 14, 2024	green andrew m	sold	-79,880	20.00	-3,994	vp regulatory
Mar 12, 2024	getz matthew a	sold	-99,719	19.9439	-5,000	vp, human resources
Mar 05, 2024	stanton marshall s.	sold	-28,195	18.7221	-1,506	svp, clinical & md affair
Mar 05, 2024	davis john e	sold	-37,856	18.7222	-2,022	chief commercial officer
Mar 05, 2024	holloway jean f	sold	-44,558	18.7222	-2,380	svp, general counsel
Mar 05, 2024	green andrew m	sold	-21,717	18.7221	-1,160	vp regulatory
Mar 05, 2024	maney rochelle l.	sold	-21,661	18.7224	-1,157	vp, quality

Which funds bought or sold AORT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 19, 2024	State of Alaska, Department of Revenue	reduced	-0.98	74,000	502,000	0.01%
Apr 19, 2024	Maryland State Retirement & Pension System	unchanged	-	32,827	289,602	0.01%
Apr 19, 2024	Mesirow Financial Investment Management, Inc.	reduced	-22.97	-27,479	269,705	1.34%
Apr 19, 2024	VALLEY NATIONAL ADVISERS INC	unchanged	-	-	1,000	-%
Apr 18, 2024	FARMERS & MERCHANTS INVESTMENTS INC	unchanged	-	108	698	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	291	92,577	118,073	-%
Apr 18, 2024	Park Place Capital Corp	unchanged	-	489	3,153	-%
Apr 18, 2024	WASATCH ADVISORS LP	added	108	13,648,200	22,928,300	0.12%
Apr 16, 2024	Register Financial Advisors LLC	new	-	114,276	114,276	0.06%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	reduced	-1.71	149,497	1,065,360	0.03%

Are Funds Buying or Selling AORT?

Are funds buying AORT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AORT

No. of Funds

Unveiling Artivion, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	perceptive advisors llc	5.8%	2,383,978	SC 13G
Feb 14, 2024	macquarie group ltd	7%	2,873,431	SC 13G/A
Feb 13, 2024	vanguard group inc	6.41%	2,630,873	SC 13G/A
Feb 12, 2024	morgan stanley	5.8%	2,375,713	SC 13G/A
Feb 08, 2024	wellington management group llp	5.99%	2,459,646	SC 13G/A
Jan 22, 2024	blackrock inc.	16.7%	6,844,308	SC 13G/A
Feb 14, 2023	macquarie group ltd	6.60%	2,662,637	SC 13G/A
Feb 10, 2023	wasatch advisors inc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	6.97%	2,809,140	SC 13G/A
Feb 08, 2023	morgan stanley	5.4%	2,189,557	SC 13G

Recent SEC filings of Artivion, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 01, 2024	ARS	ARS
Apr 01, 2024	DEF 14A	DEF 14A
Apr 01, 2024	DEFA14A	DEFA14A
Mar 21, 2024	4	Insider Trading
Mar 21, 2024	PRE 14A	PRE 14A
Mar 18, 2024	4	Insider Trading
Mar 15, 2024	144	Notice of Insider Sale Intent
Mar 15, 2024	4	Insider Trading
Mar 14, 2024	4/A	Insider Trading
Mar 14, 2024	4/A	Insider Trading

Peers (Alternatives to Artivion, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.8B	40.1B	-3.17%	-4.12%	32.46	4.63	-8.12%	-17.45%
BDX	67.6B	19.5B	-4.91%	-10.36%	53.86	3.47	4.02%	-22.04%
ALGN	22.6B	3.9B	-5.82%	-15.30%	50.76	5.85	3.42%	23.09%
BAX	20.5B	14.8B	-3.67%	-10.80%	7.72	1.39	2.12%	209.17%
MID-CAP
ATR	9.3B	3.5B	-0.90%	16.36%	32.56	2.66	4.97%	18.89%
HSIC	9.3B	12.3B	-1.49%	-14.91%	22.25	0.75	-2.44%	-22.68%
BIO	8.2B	2.7B	-20.12%	-40.09%	-12.83	3.06	-4.68%	82.43%
XRAY	6.3B	4.0B	-7.30%	-26.11%	-46.81	1.59	1.10%	85.84%
AXNX	3.4B	366.4M	-2.14%	10.95%	-561.72	9.3	33.86%	89.83%
PDCO	2.3B	6.6B	-4.88%	-5.43%	11.99	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-13.12%	-21.63%	-1.88	0.4	7.73%	-1066.14%
ANIK	385.4M	166.7M	2.04%	-4.03%	-4.66	2.31	6.67%	-456.34%
ANGO	250.7M	324.0M	16.79%	-29.66%	-1.3	0.77	-3.19%	-337.41%
APYX	43.7M	52.3M	1.60%	-56.21%	-2.33	0.83	17.61%	19.28%
AEMD	3.9M	3.7M	-13.45%	142.62%	-0.32	1.03	5.77%	8.23%

Artivion, Inc. News

Latest updates

Artivion, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	6.6%	94.00	88.00	89.00	83.00	79.00	77.00	80.00	77.00	79.00	72.00	76.00	71.00	68.00	65.00	54.00	66.00	70.00	68.00	71.00	68.00	68.00
Gross Profit	8.6%	61.00	56.00	58.00	54.00	51.00	49.00	52.00	51.00	51.00	48.00	51.00	48.00	45.00	43.00	36.00	44.00	47.00	45.00	47.00	44.00	45.00
Operating Expenses	0.7%	58.00	58.00	65.00	58.00	47.00	53.00	48.00	49.00	61.00	49.00	49.00	46.00	43.00	39.00	38.00	45.00	43.00	41.00	40.00	42.00	42.00
S&GA Expenses	-1.6%	50.00	51.00	57.00	50.00	38.00	41.00	39.00	39.00	51.00	39.00	41.00	39.00	36.00	34.00	32.00	39.00	38.00	34.00	35.00	37.00	36.00
R&D Expenses	19.1%	8.00	6.00	7.00	7.00	8.00	12.00	9.00	10.00	9.00	10.00	8.00	8.00	7.00	6.00	6.00	6.00	5.00	6.00	6.00	6.00	7.00
EBITDA Margin	-12.5%	0.08*	0.09*	0.07*	0.07*	0.08*	0.02*	0.08*	0.09*	0.09*	0.15*	0.10*	0.10*	-	-	-	-	-	-	-	-	-
Interest Expenses	-5.4%	6.00	7.00	6.00	6.00	5.00	5.00	4.00	4.00	4.00	4.00	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	785.9%	3.00	0.00	1.00	5.00	1.00	1.00	1.00	1.00	4.00	-2.64	0.00	-1.36	3.00	-1.31	-1.08	-1.47	2.00	-0.86	-0.09	-1.35	-0.68
Earnings Before Taxes	93.7%	-0.59	-9.42	-2.66	-8.92	3.00	-12.53	-3.30	-2.43	-16.09	8.00	-2.18	-4.50	-0.09	-4.18	-4.77	-8.13	2.00	-0.99	3.00	-1.65	-1.46
EBT Margin	-16.9%	-0.06*	-0.05*	-0.06*	-0.07*	-0.05*	-0.11*	-0.04*	-0.04*	-0.05*	0.00*	-0.04*	-0.05*	-	-	-	-	-	-	-	-	-
Net Income	59.4%	-3.97	-9.80	-3.38	-13.53	2.00	-13.71	-4.26	-3.39	-20.10	11.00	-2.18	-3.14	-3.46	-2.87	-3.69	-6.66	-0.68	-0.13	3.00	-0.30	-0.78
Net Income Margin	-20.0%	-0.09*	-0.07*	-0.09*	-0.09*	-0.06*	-0.13*	-0.06*	-0.05*	-0.05*	0.01*	-0.04*	-0.05*	-	-	-	-	-	-	-	-	-
Free Cashflow	54.8%	9.00	6.00	5.00	-8.39	-2.31	1.00	-10.13	-2.84	-1.85	-6.18	-3.10	-4.54	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	2.3%	792	775	778	757	763	743	765	782	793	819	810	795	789	782	693	621	606	593	597	587	571
Current Assets	5.1%	281	267	264	241	247	238	240	245	248	257	238	236	235	234	287	214	187	181	189	179	179
Cash Equivalents	10.2%	59.00	53.00	49.00	31.00	39.00	38.00	40.00	51.00	55.00	65.00	51.00	57.00	62.00	65.00	126	64.00	34.00	37.00	40.00	41.00	42.00
Inventory	4.0%	82.00	79.00	78.00	76.00	74.00	73.00	74.00	76.00	77.00	78.00	76.00	73.00	73.00	69.00	63.00	54.00	53.00	48.00	45.00	44.00	45.00
Net PPE	-100.0%	-	37.00	38.00	39.00	39.00	36.00	36.00	37.00	38.00	37.00	36.00	31.00	33.00	32.00	32.00	32.00	32.00	30.00	31.00	30.00	31.00
Goodwill	1.8%	247	243	246	246	244	235	241	248	250	252	255	254	260	254	186	184	187	183	188	187	189
Liabilities	1.6%	511	503	495	477	478	488	483	484	492	507	509	498	461	456	397	344	320	315	315	314	296
Current Liabilities	5.3%	58.00	55.00	56.00	44.00	50.00	46.00	42.00	43.00	45.00	61.00	59.00	58.00	60.00	54.00	49.00	44.00	45.00	42.00	37.00	36.00	35.00
Long Term Debt	-0.1%	306	306	306	306	306	307	307	307	307	308	308	310	290	290	289	244	215	215	215	215	216
LT Debt, Current	-6.5%	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
LT Debt, Non Current	-0.1%	306	306	306	306	306	307	307	307	307	308	308	310	290	290	289	244	215	215	215	215	216
Shareholder's Equity	3.6%	282	272	283	280	284	255	282	297	301	312	302	297	329	326	297	277	286	278	282	273	275
Retained Earnings	-9.0%	-47.91	-43.93	-34.13	-30.75	-17.22	-19.39	-5.67	-1.41	2.00	22.00	11.00	14.00	20.00	23.00	26.00	30.00	37.00	37.00	38.00	35.00	35.00
Additional Paid-In Capital	1.3%	356	351	347	343	337	334	330	327	323	309	305	301	316	316	293	274	272	269	266	262	260
Accumulated Depreciation	-	-	-	-	-	-	-	-	-	-	-	-	-	78.00	-	-	-	71.00	-	-	-	65.00
Shares Outstanding	-4.2%	41.00	43.00	42.00	42.00	40.00	40.00	40.00	40.00	39.00	39.00	39.00	39.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	666	-	-	-	725	-	-	-	1,070	-	-	-	694	-	-	-	1,078	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	49.9%	10,838	7,232	6,909	-6,154	-217	3,976	-8,314	-598	716	-2,909	2,647	-3,039	5,450	7,679	-3,395	2,635	1,060	12,860	746	1,161	10,521
Share Based Compensation	24.1%	3,956	3,187	3,938	3,341	3,155	3,089	2,934	3,166	3,240	2,876	2,115	2,480	-520	2,358	2,510	2,564	2,218	2,462	2,269	1,850	1,640
Cashflow From Investing	-29.1%	-2,669	-2,068	7,078	-2,843	-2,668	-3,053	-2,286	-2,708	-2,812	15,516	-6,234	-810	-2,346	-66,301	-1,578	-2,903	-3,190	-17,107	-2,219	-1,427	-1,718
Cashflow From Financing	-79.3%	-1,630	-909	2,233	1,171	-859	252	-797	-235	-8,801	315	-1,642	-2,095	-1,682	-896	67,671	28,515	-657	-12.00	391	-1,215	-1,284

AORT Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 354,004	$ 313,789	$ 298,836
Cost of products and preservation services:
Total cost of products and preservation services	124,828	111,266	101,322
Gross margin	229,176	202,523	197,514
Operating expenses:
General, administrative, and marketing	208,977	157,443	169,774
Research and development	28,707	38,879	35,546
Total operating expenses	237,684	196,322	205,320
Gain from sale of non-financial assets	14,250	0	15,923
Operating income	5,742	6,201	8,117
Interest expense	25,299	18,224	16,887
Interest income	(1,077)	(147)	(79)
Other expense, net	3,106	3,108	6,136
Loss before income taxes	(21,586)	(14,984)	(14,827)
Income tax expense	9,104	4,208	7
Net loss	$ (30,690)	$ (19,192)	$ (14,834)
Loss per share:
Basic (in dollars per share)	$ (0.75)	$ (0.48)	$ (0.38)
Diluted (in dollars per share)	$ (0.75)	$ (0.48)	$ (0.38)
Weighted-average common shares outstanding:
Basic (in shares)	40,743	40,032	38,983
Diluted (in shares)	40,743	40,032	38,983
Net loss	$ (30,690)	$ (19,192)	$ (14,834)
Other comprehensive income (loss):
Foreign currency translation adjustments	9,599	(11,722)	(16,630)
Comprehensive loss	(21,091)	(30,914)	(31,464)
Products
Revenues:
Total revenues	261,185	230,353	221,597
Cost of products and preservation services:
Total cost of products and preservation services	84,595	72,166	65,196
Preservation services
Revenues:
Total revenues	92,819	83,436	77,239
Cost of products and preservation services:
Total cost of products and preservation services	$ 40,233	$ 39,100	$ 36,126

AORT Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 58,940	$ 39,351
Trade receivables, net	71,796	61,820
Other receivables	2,342	7,764
Inventories, net	81,976	74,478
Deferred preservation costs, net	49,804	46,371
Prepaid expenses and other	15,810	17,550
Total current assets	280,668	247,334
Goodwill	247,337	243,631
Acquired technology, net	142,593	151,263
Operating lease right-of-use assets, net	43,822	41,859
Property and equipment, net	38,358	38,674
Other intangibles, net	29,638	31,384
Deferred income taxes	1,087	1,314
Other long-term assets	8,894	7,339
Total assets	792,397	762,798
Current liabilities:
Accounts payable	13,318	12,004
Accrued compensation	18,715	13,810
Accrued expenses	12,732	12,374
Taxes payable	3,840	2,635
Current maturities of operating leases	3,395	3,308
Current portion of long-term debt	1,451	1,608
Accrued procurement fees	1,439	2,111
Current portion of finance lease obligation	582	513
Other	2,390	1,312
Total current liabilities	57,862	49,675
Long-term debt	305,531	306,499
Contingent consideration	63,890	40,400
Non-current maturities of operating leases	43,977	41,257
Deferred income taxes	21,851	24,499
Deferred compensation liability	6,760	5,468
Non-current finance lease obligations	3,405	3,644
Other	7,341	7,027
Total liabilities	510,617	478,469
Commitments and contingencies
Shareholders' equity:
Preferred stock $0.01 par value per share, 5,000 shares authorized, no shares issued	0	0
Common stock $0.01 par value per share, 75,000 shares authorized, 42,569 and 41,830 shares issued as of December 31, 2023 and 2022, respectively	426	418
Additional paid-in capital	355,919	337,385
Retained deficit	(47,907)	(17,217)
Accumulated other comprehensive loss	(12,010)	(21,609)
Treasury stock at cost, 1,487 shares as of December 31, 2023 and 2022	(14,648)	(14,648)
Total shareholders' equity	281,780	284,329
Total liabilities and shareholders' equity	$ 792,397	$ 762,798

About Artivion, Inc.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent and graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.

CEO	Mr. James Patrick Mackin
WEBSITE	https://artivion.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	1300

Artivion, Inc. Frequently Asked Questions

What is the ticker symbol for Artivion, Inc.? What does AORT stand for in stocks?

AORT is the stock ticker symbol of Artivion, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Artivion, Inc. (AORT)?

As of Mon Apr 22 2024, market cap of Artivion, Inc. is 837.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AORT stock?

You can check AORT's fair value in chart for subscribers.

What is the fair value of AORT stock?

You can check AORT's fair value in chart for subscribers. The fair value of Artivion, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Artivion, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AORT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Artivion, Inc. a good stock to buy?

The fair value guage provides a quick view whether AORT is over valued or under valued. Whether Artivion, Inc. is cheap or expensive depends on the assumptions which impact Artivion, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AORT.

What is Artivion, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 22 2024, AORT's PE ratio (Price to Earnings) is -27.3 and Price to Sales (PS) ratio is 2.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AORT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Artivion, Inc.'s stock?

In the past 10 years, Artivion, Inc. has provided 0.081 (multiply by 100 for percentage) rate of return.